Meeting an un-MET need: Targeting MET in non-small cell lung cancer
The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). MET exon 14 skipping mutations occur in 3-4% of patients with NSCLC, while MET amplifi...
| Prif Awduron: | , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
Frontiers Media S.A.
2022-10-01
|
| Cyfres: | Frontiers in Oncology |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1004198/full |